KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Capital Expenditures: 2011-2025

Historic Capital Expenditures for Sarepta Therapeutics (SRPT) over the last 15 years, with Sep 2025 value amounting to $22.9 million.

  • Sarepta Therapeutics' Capital Expenditures fell 38.45% to $22.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $136.5 million, marking a year-over-year increase of 15.73%. This contributed to the annual value of $137.0 million for FY2024, which is 79.95% up from last year.
  • Per Sarepta Therapeutics' latest filing, its Capital Expenditures stood at $22.9 million for Q3 2025, which was down 27.87% from $31.8 million recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Capital Expenditures registered a high of $43.7 million during Q1 2025, and its lowest value of $2.2 million during Q4 2021.
  • Moreover, its 3-year median value for Capital Expenditures was $29.7 million (2023), whereas its average is $28.3 million.
  • Per our database at Business Quant, Sarepta Therapeutics' Capital Expenditures plummeted by 92.29% in 2021 and then spiked by 261.02% in 2022.
  • Over the past 5 years, Sarepta Therapeutics' Capital Expenditures (Quarterly) stood at $2.2 million in 2021, then soared by 261.02% to $8.0 million in 2022, then surged by 139.06% to $19.0 million in 2023, then skyrocketed by 100.02% to $38.1 million in 2024, then plummeted by 38.45% to $22.9 million in 2025.
  • Its Capital Expenditures stands at $22.9 million for Q3 2025, versus $31.8 million for Q2 2025 and $43.7 million for Q1 2025.